Malaysia
Search
Sign In
Dermatology
Top Medical News
Patients with psoriasis report improved quality of life under the COVID-19 pandemic despite harsh movement restrictions, a recent study has found. Such an effect, however, may suggest that current tools do not completely capture the negative impacts of harsh lockdowns on patients’ wellbeing.
Treatment with deucravacitinib achieves better efficacy than placebo and apremilast in patients with moderate-to-severe plaque psoriasis, while also yielding a good safety profile, reports a recent study.
Among adults and adolescents with atopic dermatitis (AD), ruxolitinib cream helps sustainably improve itching, reports a recent analysis.
In the treatment of children with atopic eczema, ciclosporin is linked to a more rapid response while methotrexate (MTX) is associated with sustained disease control following discontinuation, a study has found.
In acral melanoma (AM) patients with Breslow thickness >2 mm, tumour thickness does not appear to affect survival, a recent study has found.
Applying roflumilast cream topically once-a-day helps clear plaque psoriasis in 8 weeks, according to pooled data from the phase III DERMIS-1 and DERMIS-2 trials.
Rocatinlimab improved disease severity in patients with moderate-to-severe head and neck atopic dermatitis (H&N AD), a post hoc analysis of a phase IIb trial has shown.
Special Reports
Bifonazole Anti-Fungal Cream 1% w/w
Furfuryl Palmitate
Oral H1-antihistamines are the initial treatment of choice for allergic rhinitis (AR) and chronic urticaria in the primary care setting. However, in a diverse population of patients with AR and urticaria, primary care physicians are faced with the challenge of prescribing the best therapy amid a wide armamentarium of antihistamines available.
The prevalence of allergic diseases in the Asia-Pacific region is expected to rise over the next 20 years, driven by rapid economic development and urbanization. Allergic diseases have high socioeconomic impact by impairing productivity and quality of life, and the impact may be greater in Asia-Pacific than in Europe due to the presence and predominance of perennial allergens.
DCH Auriga recently held their first Aesthetics and Suturing Workshop under the IMPACT continuing medical education series – a scientific platform that aims to cascade the latest updates on disease management and share best clinical practices among healthcare professionals in Singapore. Two experts on aesthetics and aesthetic surgery shared their insights on suturing techniques and current approaches for scar prevention and management.
Eczema (atopic dermatitis) is a chronic inflammatory skin disease that
can present in many different forms. However, it is principally
characterized by dry skin, intense itching, and the presence of
inflammatory skin lesions. [J Eur Acad Dermatol Venereol
2016;30:604-618; N Engl J Med 2008;358:1483-1494; Lancet
2016;387:1109-1122]
Conference Reports
Rocatinlimab improved disease severity in patients with moderate-to-severe head and neck atopic dermatitis (H&N AD), a post hoc analysis of a phase IIb trial has shown.
In the interim analysis of the ongoing phase III ALLEGRO-LT trial, the investigational oral JAK3*/TEC inhibitor ritlecitinib demonstrated long-term safety and remarkable scalp hair regrowth in adults and adolescents with alopecia areata (AA).
In the phase III STRATUM* trial, the investigational PDE4** inhibitor roflumilast improved multiple symptoms of moderate-to-severe seborrheic dermatitis (SD).
A once-daily dose of oral baricitinib may encourage hair regrowth in patients with severe alopecia areata, according to results of the phase III BRAVE-AA studies presented at AAD 2022.
The human monoclonal IgG4 antibody dupilumab effectively treats prurigo nodularis (PN), including itching and skin lesions, weeks after treatment in the phase III randomized, double-blind, LIBERTY-PN PRIME2 trial. Hopefully, this brings relief to patients suffering from uncontrolled PN.
Using a topical roflumilast cream to treat patients with chronic plaque psoriasis yields a significant improvement in disease severity, achieving a clear or almost clear IGA* status, based on a pooled analysis of the DERMIS-1** and DERMIS-2*** studies presented at AAD 2022.
Skin reactions to the first COVID-19 vaccine in some individuals shouldn’t be a reason to leave out the second dose, or a scheduled booster if tolerable, according to an analysis presented at AAD 2022.
